73/100B904.38
USD
1.56
(0.17%)
Pre Open·910.20USD+5.82(+0.64%)
Last updated: · Delayed 15 min
Fair value814.64Plus+11%346Price 904.381,431
Q4 FY2026 · Earnings report
EPS estimate 25.39Revenue estimate 5.85B
Q4 FY2026 · Earnings report
EPS estimate 25.39Revenue estimate 5.85B
Regeneron Pharmaceuticals price to sales (P/S) ratioWhat is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
Regeneron Pharmaceuticals's P/S ratio is 5.54: its market cap of 93.54B USD over revenue of 16.90B USD in the last twelve months.
- Today
- 5.54
- Average, 5 years
- 5.87
- Low, 5 years
- 3.66
- High, 5 years
- 9.63
P/S ratio = market cap ÷ revenue (last 12 months) = 93.54B ÷ 16.90B = 5.54
Each day's market cap over the revenue of the last four quarters reported by that day.
P/S ratio by year and by quarter
| Fiscal year | Period ending | P/S ratio | Market cap | Revenue |
|---|---|---|---|---|
| Today | 5.54 | 93.54B | 16.90B | |
| FY2025 | 31 Dec 2025 | 5.63 | 80.74B | 14.34B |
| FY2024 | 31 Dec 2024 | 5.41 | 76.86B | 14.20B |
| FY2023 | 31 Dec 2023 | 7.14 | 93.71B | 13.12B |
| FY2022 | 31 Dec 2022 | 6.35 | 77.27B | 12.17B |
| FY2021 | 31 Dec 2021 | 4.15 | 66.75B | 16.07B |
| FY2020 | 31 Dec 2020 | 6.12 | 51.98B | 8.50B |
| FY2019 | 31 Dec 2019 | 6.25 | 41.00B | 6.56B |
| FY2018 | 31 Dec 2018 | 6.39 | 42.88B | 6.71B |
| FY2017 | 31 Dec 2017 | 7.42 | 43.57B | 5.87B |
| FY2016 | 31 Dec 2016 | 8.78 | 42.67B | 4.86B |
| FY2015 | 31 Dec 2015 | 15.24 | 62.55B | 4.10B |
| FY2014 | 31 Dec 2014 | 16.50 | 46.53B | 2.82B |
| FY2013 | 31 Dec 2013 | 14.54 | 30.61B | 2.10B |
| FY2012 | 31 Dec 2012 | 13.78 | 19.00B | 1.38B |
| FY2011 | 31 Dec 2011 | 11.27 | 5.02B | 445.82M |
| FY2010 | 31 Dec 2010 | 5.93 | 2.72B | 459.07M |
| FY2009 | 31 Dec 2009 | 5.09 | 1.93B | 379.27M |
| FY2008 | 31 Dec 2008 | 6.07 | 1.45B | 238.46M |
| FY2007 | 31 Dec 2007 | 12.81 | 1.60B | 125.02M |
| FY2006 | 31 Dec 2006 | 18.34 | 1.16B | 63.45M |
| FY2005 | 31 Dec 2005 | 13.44 | 889.61M | 66.19M |
| FY2004 | 31 Dec 2004 | 2.93 | 510.41M | 174.02M |
| FY2003 | 31 Dec 2003 | 12.91 | 742.12M | 57.50M |
| FY2002 | 31 Dec 2002 | 37.00 | 813.50M | 21.99M |
| FY2001 | 31 Dec 2001 | 53.94 | 1.19B | 21.97M |
| FY2000 | 31 Dec 2000 | 20.93 | 1.24B | 59.28M |
| FY1999 | 31 Dec 1999 | 11.54 | 398.01M | 34.50M |
| FY1998 | 31 Dec 1998 | 5.93 | 226.67M | 38.20M |
| FY1997 | 31 Dec 1997 | 7.50 | 248.24M | 33.10M |
| FY1996 | 31 Dec 1996 | 16.37 | 394.60M | 24.10M |
| FY1995 | 31 Dec 1995 | 9.19 | 251.79M | 27.40M |
| FY1994 | 31 Dec 1994 | 2.45 | 56.85M | 23.20M |
| FY1993 | 31 Dec 1993 | 24.21 | 256.62M | 10.60M |
| FY1992 | 31 Dec 1992 | 16.07 | 184.84M | 11.50M |
| FY1991 | 31 Dec 1991 | 38.54 | 281.33M | 7.30M |
| FY1990 | 31 Dec 1990 | 64.93 | 324.64M | 5.00M |
| Quarter | Period ending | P/S ratio | Market cap | Revenue |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 4.56 | 77.12B | 16.90B |
| Q2 FY2026 | 30 Jun 2026 | 4.15 | 64.47B | 15.53B |
| Q1 FY2026 | 31 Mar 2026 | 5.39 | 80.35B | 14.92B |
| Q4 FY2025 | 31 Dec 2025 | 5.54 | 79.43B | 14.34B |
| Q3 FY2025 | 30 Sept 2025 | 4.09 | 58.26B | 14.25B |
| Q2 FY2025 | 30 Jun 2025 | 3.88 | 55.18B | 14.21B |
| Q1 FY2025 | 31 Mar 2025 | 4.80 | 67.67B | 14.09B |
| Q4 FY2024 | 31 Dec 2024 | 5.41 | 76.86B | 14.20B |
| Q3 FY2024 | 30 Sept 2024 | 8.21 | 113.64B | 13.85B |
| Q2 FY2024 | 30 Jun 2024 | 8.47 | 114.26B | 13.49B |
| Q1 FY2024 | 31 Mar 2024 | 7.98 | 104.49B | 13.10B |
| Q4 FY2023 | 31 Dec 2023 | 7.14 | 93.63B | 13.12B |
| Q3 FY2023 | 30 Sept 2023 | 6.68 | 87.48B | 13.10B |
| Q2 FY2023 | 30 Jun 2023 | 6.07 | 76.88B | 12.67B |
| Q1 FY2023 | 31 Mar 2023 | 7.11 | 88.00B | 12.37B |
| Q4 FY2022 | 31 Dec 2022 | 6.34 | 77.20B | 12.17B |
| Q3 FY2022 | 30 Sept 2022 | 5.67 | 77.70B | 13.71B |
| Q2 FY2022 | 30 Jun 2022 | 4.74 | 67.39B | 14.23B |
| Q1 FY2022 | 31 Mar 2022 | 4.78 | 78.97B | 16.51B |
| Q4 FY2021 | 31 Dec 2021 | 4.17 | 67.07B | 16.07B |
| Q3 FY2021 | 30 Sept 2021 | 4.75 | 64.27B | 13.54B |
| Q2 FY2021 | 30 Jun 2021 | 4.74 | 58.65B | 12.38B |
| Q1 FY2021 | 31 Mar 2021 | 5.68 | 52.28B | 9.20B |
| Q4 FY2020 | 31 Dec 2020 | 5.99 | 50.92B | 8.50B |
| Q3 FY2020 | 30 Sept 2020 | 7.44 | 59.06B | 7.94B |
| Q2 FY2020 | 30 Jun 2020 | 9.25 | 68.35B | 7.39B |
| Q1 FY2020 | 31 Mar 2020 | 8.01 | 56.17B | 7.01B |
| Q4 FY2019 | 31 Dec 2019 | 6.54 | 42.92B | 6.56B |
| Q3 FY2019 | 30 Sept 2019 | 4.78 | 31.68B | 6.62B |
| Q2 FY2019 | 30 Jun 2019 | 5.55 | 36.28B | 6.54B |
| Q1 FY2019 | 31 Mar 2019 | 7.21 | 47.36B | 6.57B |
| Q4 FY2018 | 31 Dec 2018 | 6.39 | 42.86B | 6.71B |
| Q3 FY2018 | 30 Sept 2018 | 7.12 | 45.35B | 6.37B |
| Q2 FY2018 | 30 Jun 2018 | 6.36 | 39.47B | 6.20B |
| Q1 FY2018 | 31 Mar 2018 | 6.52 | 39.57B | 6.06B |
| Q4 FY2017 | 31 Dec 2017 | 7.42 | 43.56B | 5.87B |
| Q3 FY2017 | 30 Sept 2017 | 9.48 | 52.30B | 5.52B |
| Q2 FY2017 | 30 Jun 2017 | 10.89 | 57.02B | 5.24B |
| Q1 FY2017 | 31 Mar 2017 | 8.96 | 44.60B | 4.98B |
| Q4 FY2016 | 31 Dec 2016 | 8.75 | 42.50B | 4.86B |
| Q3 FY2016 | 30 Sept 2016 | 9.90 | 46.82B | 4.73B |
| Q2 FY2016 | 30 Jun 2016 | 8.72 | 40.55B | 4.65B |
| Q1 FY2016 | 31 Mar 2016 | 9.28 | 41.16B | 4.43B |
| Q4 FY2015 | 31 Dec 2015 | 15.28 | 62.70B | 4.10B |
| Q3 FY2015 | 30 Sept 2015 | 14.15 | 53.89B | 3.81B |
| Q2 FY2015 | 30 Jun 2015 | 17.30 | 58.75B | 3.40B |
| Q1 FY2015 | 31 Mar 2015 | 16.88 | 51.70B | 3.06B |
| Q4 FY2014 | 31 Dec 2014 | 16.62 | 46.87B | 2.82B |
| Q3 FY2014 | 30 Sept 2014 | 15.59 | 40.96B | 2.63B |
| Q2 FY2014 | 30 Jun 2014 | 12.78 | 31.93B | 2.50B |
| Q1 FY2014 | 31 Mar 2014 | 14.68 | 33.62B | 2.29B |
| Q4 FY2013 | 31 Dec 2013 | 14.72 | 30.98B | 2.10B |
| Q3 FY2013 | 30 Sept 2013 | 18.52 | 35.35B | 1.91B |
| Q2 FY2013 | 30 Jun 2013 | 14.63 | 25.45B | 1.74B |
| Q1 FY2013 | 31 Mar 2013 | 12.31 | 19.52B | 1.59B |
| Q4 FY2012 | 31 Dec 2012 | 13.70 | 18.89B | 1.38B |
| Q3 FY2012 | 30 Sept 2012 | 15.85 | 17.22B | 1.09B |
| Q2 FY2012 | 30 Jun 2012 | 14.18 | 10.80B | 762.00M |
| Q1 FY2012 | 31 Mar 2012 | 19.27 | 10.90B | 565.41M |
| Q4 FY2011 | 31 Dec 2011 | 11.41 | 5.09B | 445.82M |
| Q3 FY2011 | 30 Sept 2011 | 11.61 | 5.30B | 456.52M |
| Q2 FY2011 | 30 Jun 2011 | 11.16 | 5.13B | 459.67M |
| Q1 FY2011 | 31 Mar 2011 | 8.57 | 4.01B | 467.74M |
| Q4 FY2010 | 31 Dec 2010 | 6.25 | 2.87B | 459.07M |
| Q3 FY2010 | 30 Sept 2010 | 5.30 | 2.24B | 422.20M |
| Q2 FY2010 | 30 Jun 2010 | 4.19 | 1.82B | 433.68M |
| Q1 FY2010 | 31 Mar 2010 | 5.27 | 2.15B | 407.82M |
| Q4 FY2009 | 31 Dec 2009 | 5.11 | 1.94B | 379.27M |
| Q3 FY2009 | 30 Sept 2009 | 4.56 | 1.54B | 338.31M |
| Q2 FY2009 | 30 Jun 2009 | 4.98 | 1.43B | 286.43M |
| Q1 FY2009 | 31 Mar 2009 | 4.29 | 1.10B | 257.06M |
| Q4 FY2008 | 31 Dec 2008 | 6.10 | 1.45B | 238.46M |
| Q3 FY2008 | 30 Sept 2008 | 6.97 | 1.72B | 247.35M |
| Q2 FY2008 | 30 Jun 2008 | 5.57 | 1.14B | 204.08M |
| Q1 FY2008 | 31 Mar 2008 | 9.09 | 1.51B | 165.62M |
| Q4 FY2007 | 31 Dec 2007 | 15.16 | 1.90B | 125.02M |
| Q3 FY2007 | 30 Sept 2007 | 17.27 | 1.22B | 70.64M |
| Q2 FY2007 | 30 Jun 2007 | 18.48 | 1.18B | 63.95M |
| Q1 FY2007 | 31 Mar 2007 | 23.23 | 1.42B | 61.02M |
| Q4 FY2006 | 31 Dec 2006 | 20.74 | 1.32B | 63.45M |
| Q3 FY2006 | 30 Sept 2006 | 12.68 | 894.50M | 70.53M |
| Q2 FY2006 | 30 Jun 2006 | 10.26 | 729.65M | 71.10M |
| Q1 FY2006 | 31 Mar 2006 | 13.83 | 943.37M | 68.20M |
| Q4 FY2005 | 31 Dec 2005 | 13.47 | 891.85M | 66.19M |
| Q3 FY2005 | 30 Sept 2005 | 5.54 | 531.23M | 95.86M |
| Q2 FY2005 | 30 Jun 2005 | 4.04 | 469.14M | 116.18M |
| Q1 FY2005 | 31 Mar 2005 | 2.22 | 285.21M | 128.24M |
| Q4 FY2004 | 31 Dec 2004 | 2.94 | 511.54M | 174.02M |
| Q3 FY2004 | 30 Sept 2004 | 3.25 | 481.46M | 148.20M |
| Q2 FY2004 | 30 Jun 2004 | 4.52 | 583.18M | 129.07M |
| Q1 FY2004 | 31 Mar 2004 | 6.75 | 750.74M | 111.19M |
| Q4 FY2003 | 31 Dec 2003 | 13.64 | 809.01M | 59.33M |
| Q3 FY2003 | 30 Sept 2003 | 21.67 | 931.07M | 42.97M |
| Q2 FY2003 | 30 Jun 2003 | 24.30 | 781.16M | 32.15M |
| Q1 FY2003 | 31 Mar 2003 | 12.25 | 332.98M | 27.18M |
| Q4 FY2002 | 31 Dec 2002 | 37.14 | 816.53M | 21.99M |
| Q3 FY2002 | 30 Sept 2002 | 27.63 | 593.33M | 21.48M |
| Q2 FY2002 | 30 Jun 2002 | 29.99 | 611.55M | 20.39M |
| Q1 FY2002 | 31 Mar 2002 | 54.05 | 1.11B | 20.60M |
| Q4 FY2001 | 31 Dec 2001 | 49.68 | 1.23B | 24.75M |
| Q3 FY2001 | 30 Sept 2001 | 24.76 | 984.42M | 39.76M |
| Q2 FY2001 | 30 Jun 2001 | 30.74 | 1.51B | 49.19M |
| Q1 FY2001 | 31 Mar 2001 | 14.36 | 830.66M | 57.86M |
| Q4 FY2000 | 31 Dec 2000 | 22.16 | 1.31B | 59.28M |
| Q3 FY2000 | 30 Sept 2000 | 22.78 | 1.18B | 51.76M |
| Q2 FY2000 | 30 Jun 2000 | 22.67 | 1.09B | 48.15M |
| Q1 FY2000 | 31 Mar 2000 | 23.75 | 940.52M | 39.60M |
| Q4 FY1999 | 31 Dec 1999 | 11.25 | 389.09M | 34.60M |
| Q3 FY1999 | 30 Sept 1999 | 8.27 | 248.98M | 30.10M |
| Q2 FY1999 | 30 Jun 1999 | 8.23 | 243.67M | 29.60M |
| Q1 FY1999 | 31 Mar 1999 | 5.47 | 203.47M | 37.20M |
| Q4 FY1998 | 31 Dec 1998 | 5.77 | 220.35M | 38.20M |
| Q3 FY1998 | 30 Sept 1998 | 6.38 | 269.15M | 42.20M |
| Q2 FY1998 | 30 Jun 1998 | 6.86 | 276.60M | 40.30M |
| Q1 FY1998 | 31 Mar 1998 | 7.00 | 233.70M | 33.40M |
| Q4 FY1997 | 31 Dec 1997 | 8.17 | 270.34M | 33.10M |
| Q3 FY1997 | 30 Sept 1997 | 12.57 | 354.35M | 28.20M |
| Q2 FY1997 | 30 Jun 1997 | 10.68 | 272.24M | 25.50M |
| Q1 FY1997 | 31 Mar 1997 | 8.18 | 205.22M | 25.10M |
| Q4 FY1996 | 31 Dec 1996 | 17.17 | 413.77M | 24.10M |
| Q3 FY1996 | 30 Sept 1996 | 21.88 | 511.88M | 23.40M |
| Q2 FY1996 | 30 Jun 1996 | 18.07 | 422.90M | 23.40M |
| Q1 FY1996 | 31 Mar 1996 | 11.46 | 284.14M | 24.80M |
| Q4 FY1995 | 31 Dec 1995 | 10.72 | 284.14M | 26.50M |
| Q3 FY1995 | 30 Sept 1995 | 10.56 | 299.93M | 28.40M |
| Q2 FY1995 | 30 Jun 1995 | 5.79 | 180.00M | 31.10M |
| Q1 FY1995 | 31 Mar 1995 | 4.40 | 119.32M | 27.10M |
| Q4 FY1994 | 31 Dec 1994 | 2.46 | 57.14M | 23.20M |
| Q3 FY1994 | 30 Sept 1994 | 5.05 | 92.95M | 18.40M |
| Q2 FY1994 | 30 Jun 1994 | 6.49 | 85.00M | 13.10M |
| Q1 FY1994 | 31 Mar 1994 | 11.96 | 129.15M | 10.80M |
| Q4 FY1993 | 31 Dec 1993 | 25.91 | 256.55M | 9.90M |
| Q3 FY1993 | 30 Sept 1993 | 27.59 | 256.55M | 9.30M |
| Q2 FY1993 | 30 Jun 1993 | 31.39 | 254.26M | 8.10M |
| Q1 FY1993 | 31 Mar 1993 | 23.25 | 232.50M | 10.00M |
| Q4 FY1992 | 31 Dec 1992 | 16.07 | 183.16M | 11.40M |
| Q3 FY1992 | 30 Sept 1992 | 11.69 | 129.74M | 11.10M |
| Q2 FY1992 | 30 Jun 1992 | 16.36 | 173.44M | 10.60M |
| Q1 FY1992 | 31 Mar 1992 | 26.33 | 239.64M | 9.10M |
| Q4 FY1991 | 31 Dec 1991 | 35.78 | 271.95M | 7.60M |
| Q3 FY1991 | 30 Sept 1991 | 32.07 | 221.25M | 6.90M |
| Q2 FY1991 | 30 Jun 1991 | 26.50 | 166.95M | 6.30M |
| Q1 FY1991 | 31 Mar 1991 | 55.97 | 324.64M | 5.80M |
| Q4 FY1990 | 31 Dec 1990 | 64.93 | 324.64M | 5.00M |
| Q3 FY1990 | 30 Sept 1990 | — | 324.64M | — |
| Q2 FY1990 | 30 Jun 1990 | — | 324.64M | — |
| Q1 FY1990 | 31 Mar 1990 | — | 324.64M | — |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:P/E ratio,Market cap,Dividend yield,ROE (return on equity),Debt to equity,Current ratio,All ratios
Common questions about Regeneron Pharmaceuticals's P/S ratio
Source: Financial Modeling Prep